Antibody to GALP and uses thereof
View Patent ↗The present invention intends to provide a novel monoclonal antibody having a binding specificity to GALP or its derivative, which is useful in developing therapeutic agents, preventive agents or diagnostic agent for diseases associated with GALP or its derivative, and a method of quantifying GALP using the antibody. More specifically, the present invention provides an antibody specifically reacting with a partial peptide in the C-terminal region of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or its derivative, and a method of quantifying GALP or its derivative.
1. An isolated antibody specifically reacting with the partial peptide in the C-terminal region consisting of the 44 th –53 rd amino acid sequence in the amino acid sequence represented by SEQ ID NO:2.
2. The antibody according to claim 1 , which is labeled.
3. The antibody according to claim 1 , which is a monoclonal antibody.
4. A monoclonal antibody, which is GR-1Ca produced by a hybridoma cell GR-1C (FERM BP-7682).
5. A hybridoma cell, which produces the monoclonal antibody of claim 3 .
6. A hybridoma cell, which is GR-1C (FERM BP-7682).
7. A composition comprising the antibody according to claim 1 , and a pharmaceutically acceptable carrier.
8. A diagnostic product comprising an isolated antibody specifically reacting with the partial peptide in the C-terminal region consisting of the 44 th –53 rd amino acid sequence in the amino acid sequence represented by SEQ ID NO: 2.